The overall goal of the PFS is to stimulate innovative research relevant to mechanisms of viral persistence. This program is one mechanism through which this collaborative Study Group will facilitate the development of young investigators focused on areas relevant to the scientific mission of the HPSG and will encourage basic investigators to extend their studies into chronic viral infections, often in collaboration with members of the HPSG directly focused on these disorders. An important parallel goal is to foster the growth of young investigators, in the hope of increasing the number of workers studying these disorders. It should be emphasized that PFS awards are not designed to serve as """"""""bridge funding"""""""" for investigators """"""""between grants"""""""" or to support projects with pending support from outside funding agencies. It is anticipated that PFS recipients will lead to further, ongoing research funding by external peer-reviewed agencies as well as results warranting publication in peer-reviewed journals. Three general types of PFS applications will be considered for funding: TYPE I Those from young investigators without current or past independent NIH support establishing research programs relevant to the Aims of the HPSG. Applicants for this type of award generally hold an initial faculty appointment;senior post-doctoral fellows may also apply if there is a documented commitment by their department t a faculty appointment within the PFS support period TYPE II Those from established scientists not currently focused on chronic infection with Emerging Pathogens per se who will extend their studies to encompass issues of direct of indirect importance to understanding chronic viral infection TYPE III Those from investigators with novel projects distinctly removed from their established research program. All members of the participant HPSG institutions are eligible to receive funding through the PFS program. They are expected to attend HPSG seminars, interact with other center investigators and present their findings to the members of the HPSG in addition to formal reporting to the Executive Committee as described below. While the goals of the PFS program encompasses the three types of applications noted above, TYPE I proposals have highest priority. An investigator may not receive more than one PFS award during the HPSG grant period.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Rowe, Ian A; Tully, Damien C; Armstrong, Matthew J et al. (2016) Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 22:287-97
Fergusson, J R; Hühn, M H; Swadling, L et al. (2016) CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunol 9:401-13
Attanasio, John; Wherry, E John (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity 44:1052-68
Llibre, Alba; López-Macías, Constantino; Marafioti, Teresa et al. (2016) LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. J Immunol 196:2085-94
Kurioka, Ayako; Walker, Lucy J; Klenerman, Paul et al. (2016) MAIT cells: new guardians of the liver. Clin Transl Immunology 5:e98
van Wilgenburg, Bonnie; Scherwitzl, Iris; Hutchinson, Edward C et al. (2016) MAIT cells are activated during human viral infections. Nat Commun 7:11653
Jeffery, Hannah C; van Wilgenburg, Bonnie; Kurioka, Ayako et al. (2016) Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol 64:1118-27
Kelly, Christabel; Swadling, Leo; Capone, Stefania et al. (2016) Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 63:1455-70
Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian et al. (2016) HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep 6:22487
Swadling, Leo; Halliday, John; Kelly, Christabel et al. (2016) Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel) 4:

Showing the most recent 10 out of 128 publications